Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Gorilla Technology
GRRR
US Stock MarketDetailed Quotes
EBS Emergent BioSolutions
- 5.530
- -0.090-1.60%
Close Mar 11 16:00 ET
- 5.530
- 0.0000.00%
Post 16:07 ET
300.48MMarket Cap-1.54P/E (TTM)
5.700High5.260Low1.37MVolume5.610Open5.620Pre Close7.44MTurnover2.57%Turnover RatioLossP/E (Static)54.34MShares15.10052wk High0.62P/B295.43MFloat Cap1.82052wk Low--Dividend TTM53.42MShs Float137.610Historical High--Div YieldTTM7.83%Amplitude1.420Historical Low5.421Avg Price1Lot Size
Emergent BioSolutions Stock Forum
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Positive
Q4 Adjusted EBITDA increased 518% to $21.0 million
Smallpox MCM product revenue grew 565%
Received $550M in Medical Countermeasure Contract awards
Secured $235.8M BioThrax supply contract with DoD
Reduced debt by $168M and extended maturities to 2029
Completed $117M in asset divestitures
Negative
Q4 net loss of $31.3 million
NARCAN sales declined 41%
Anthrax MCM reve...
The price will up soon！
1 MINUTE AGO, 8:06 AM EST
VIA GLOBENEWSWIRE
Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an increase in accidental drug-related deaths year over year
The ‘Lay, Spray, Stay' opioid overdose educational video featuring Smith and how to ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Emergent BioSolutions (NYSE: EBS) has secured exclusive commercial rights to KLOXXADO® (naloxone HCl) Nasal Spray in the U.S. and Canada from Hikma Pharmaceuticals through a six-year agreement. This 8 mg naloxone product complements EBS's existing NARCAN® Nasal Spray 4 mg, expanding their portfolio of opioid overdose emergency treatments.
...
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose emergency treatments to patients, customers and communities in need
Focus remains on increasing access, ra...
$Biomea Fusion (BMEA.US)$ Covalent III Trial regarding Type 2 Diabetes mellitus out tomorrow 8AM ET. SI 44.16%. COH $62.4M good for 6.2 months
$Sidus Space (SIDU.US)$ Satellite launch Friday. May continue until launch. Low float. 0 shares LTB.COH $4.8M good for 4.2 months✅
$Maison Solutions (MSS.US)$ PR AH 12/...
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vacci...
No comment yet